Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162365 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
A Phase 1 study, sponsored by Innovent Biologics (Suzhou) Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 248
- Enrollment target
NCT05162365 is a Phase 1 study that was terminated before completion, run by Innovent Biologics (Suzhou) Co.. The registered enrollment target is 248 participants.
The verdict
NCT05162365, a Phase 1 study, was terminated before completion, sponsored by Innovent Biologics (Suzhou) Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 248 participants
- Enrollment target
Study Summary
This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.
Interventions
- OTHER Placebo
- BIOLOGICAL IBI314
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2022-01-06 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05162365
The ClinicalTrials.gov registry entry for NCT05162365 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innovent Biologics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05162365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05162365 about?
NCT05162365 is a clinical study titled "A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19". This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.
What is the current status of trial NCT05162365?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2022-01-06. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT05162365?
The interventions under investigation include: Placebo (OTHER), IBI314 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05162365?
This trial is sponsored by Innovent Biologics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.